SCHEMBL436564

SCHEMBL436564

Cc1cc(=O)n(C)c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 1.00
NQO2 P16083 2/20 1.00
HSD17B10 Q99714 2/20 0.61
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
CYP19A1 P11511 1/20 0.53
GPR3 P46089 1/20 0.52
KAT2B Q92831 2/20 0.51
HPGD P15428 4/20 0.50
ALDH1A1 P00352 2/20 0.50
KCNA3 P22001 1/20 0.50
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
CYP2C19 P33261 1/20 0.49
HTT P42858 1/20 0.49
ALKBH5 Q6P6C2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30807999 0.79 KDM4E (0.66) KDM4ENQO2HSD17B10GPR3KAT2B
SCHEMBL16247849 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10MEN1KMT2A
SCHEMBL19326885 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10MEN1KMT2A
SCHEMBL9499068 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10MEN1KMT2A
SCHEMBL12090570 0.78 NQO2 (0.65) KDM4ENQO2HSD17B10MEN1KMT2A
SCHEMBL30557144 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10KMT2AGPR3
SCHEMBL21831728 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10KMT2AGPR3
SCHEMBL29891972 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10KMT2AGPR3
SCHEMBL835056 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10MEN1KMT2A
SCHEMBL829976 0.78 KDM4E (0.65) KDM4ENQO2HSD17B10KMT2AGPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4418865-B1 LIQUID COMPOSITION CONTAINING A COMBINATION OF VITAMINS A, D, E AND K IN A LIQUID MATRIX LIPOID GMBH (DE) 2025-12-10 EP claimed
EP-3400260-B2 SCAVENGER COMPOSITIONS FOR SULFUR SPECIES INNOPHOS INC (US) 2025-03-19 EP claimed
EP-3721862-B1 ORAL CARE PREPARATIONS COMPRISING CHLORHEXIDINE AND ARGININE OR THEIR SALTS MEDA AB (SE) 2024-07-24 EP claimed
EP-3359138-B1 DIETARY SUPPLEMENTATION TO ACHIEVE OXY-REDOX HOMEOSTASIS AND EPIGENETIC STABILITY PARTHENOGEN SAGL (CH) 2024-04-24 EP claimed
EP-3691621-B1 NEUPANEX ®: NEUROPROTECTIVE, NEUROREGENERATIONAL,&NEUROGENESIS SUPPORTING SUPPLEMENT COMBINATION KILMAN CLARKE LEWIS (US) 2024-03-27 EP claimed
EP-3534915-B1 GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS XYLONIX PTE LTD (SG) 2023-12-20 EP claimed
EP-3065746-B1 ORAL REHYDRATION COMPOSITION UNIV YALE (US) 2023-03-08 EP claimed
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US claimed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US claimed
EP-4595708-A1 PLASMA TREATMENT WITH LIQUID COOLING Plasmatreat GmbH (DE) 2025-08-06 EP disclosed
WO-2024206937-A3 BI-ARYL METHYLATED LACTAM DERIVATIVES AND RELATED COMPOSITIONS AND METHOD OF USE TO INHIBIT THE PROLIFERATION OF CANCEROUS CELLS PURDUE RESEARCH FOUNDATION (US) 2024-10-31 WO disclosed
CN-115677576-B 3-Chloro-substituted quinolinone derivative and preparation method thereof 浙江树人学院 2024-04-16 CN disclosed
WO-2024068623-A1 PLASMA TREATMENT WITH LIQUID COOLING PLASMATREAT GMBH (DE) 2024-04-04 WO disclosed
WO-2023067192-A1 METHODS FOR IMPROVING ABIOTIC STRESS RESISTANCE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2023-04-27 WO disclosed
US-5658751-A SUBSTITUENTS ON PYRIDINIUM OR QUINOLINIUM RING SYSTEM SERVE TO INCREASE OR DECREASE PERMEABILITY, SELECTIVITY AND BINDING AFFINITY OF NUCLEIC ACID STAINS; FORM FLUORESCENT COMPLEXES WITH NUCLEIC ACIDS MOLECULAR PROBES, INC. (US) 1997-08-19 US disclosed
US-5656449-A STAINING NUCLEIC ACIDS MOLECULAR PROBES, INC. (US) 1997-08-12 US disclosed
WO-1996013552-A2 SUBSTITUTED UNSYMMETRICAL CYANINE DYES WITH SELECTED PERMEABILITY MOLECULAR PROBES, INC. (US) 1996-05-09 WO disclosed
EP-0675924-A1 CYCLIC-SUBSTITUTED UNSYMMETRICAL CYANINE DYES MOLECULAR PROBES, INC. (US) 1995-10-11 EP disclosed
US-5436134-A Fluorescent dyes for nucleic acids MOLECULAR PROBES, INC. (US) 1995-07-25 US disclosed
WO-1994024213-A1 CYCLIC-SUBSTITUTED UNSYMMETRICAL CYANINE DYES MOLECULAR PROBES, INC. (US) 1994-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same CBR1, POR, CAT KDM4E 3025/4885NQO2 243/4885HSD17B10 639/4885
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME CBR1, POR, CAT KDM4E 3242/4885NQO2 259/4885HSD17B10 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.